The relationship between intellectual property protection and economic development has been debated since the earliest international patent conventions. Rachel Wong’s article focused on a specific and underexplored dimension of this debate: how Central American nations could strategically deploy the flexibilities built into the GATT/TRIPS framework to accelerate technology transfer, improve access to essential medicines, and build domestic innovation capacity.
The TRIPS Framework and Its Flexibilities
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), adopted in 1994 as part of the Uruguay Round of GATT negotiations, established minimum standards for IP protection across all World Trade Organization member states. But TRIPS was not designed as a one-size-fits-all regime. Articles 7 and 8 explicitly recognized the need to balance IP protection with broader social and economic objectives, and several provisions gave developing countries tools to pursue those objectives.
Compulsory licensing, authorized under Article 31, allowed governments to permit generic production of patented products without the patent holder’s consent, subject to conditions including adequate remuneration. Parallel importation, addressed in Article 6, permitted countries to import patented goods from wherever they were sold most cheaply. The Doha Declaration on TRIPS and Public Health, adopted in 2001, affirmed that TRIPS should be interpreted in a manner supportive of WTO members’ right to protect public health.
Central America: The CAFTA-DR Constraint
Wong argued that Central American countries faced a particular challenge. The Central America-Dominican Republic Free Trade Agreement (CAFTA-DR), which entered into force between 2006 and 2009, imposed intellectual property obligations that went significantly beyond TRIPS minimum standards. These “TRIPS-plus” provisions included extended patent terms, data exclusivity requirements that delayed generic drug entry, and restrictions on the grounds for compulsory licensing.
The practical effect was to narrow the policy space that TRIPS had explicitly preserved for developing countries. Wong documented how CAFTA-DR’s IP chapters had been drafted with heavy input from the U.S. pharmaceutical and entertainment industries, whose interest in stronger IP protection abroad did not necessarily align with the development needs of Central American economies.
Access to Medicines
The most immediate impact was on access to essential medicines. Generic competition is the primary mechanism for reducing drug prices in developing countries, and TRIPS flexibilities — particularly compulsory licensing and parallel importation — were designed to enable that competition. Wong showed that CAFTA-DR’s data exclusivity provisions created an additional barrier to generic entry, independent of patent protection, by preventing generic manufacturers from relying on the originator’s clinical trial data for a period of years even after patent expiration.
The article compared the approach taken by Central American CAFTA-DR signatories with that of larger developing nations such as India, Brazil, and Thailand, which had used TRIPS flexibilities more aggressively. India’s 2005 patent law, in particular, included provisions specifically designed to prevent the “evergreening” of pharmaceutical patents — a strategy that Wong argued Central American countries could adapt to their own legal frameworks, even within CAFTA-DR constraints.
Technology Transfer and Innovation Capacity
Beyond pharmaceuticals, Wong examined how TRIPS flexibilities could support broader technology transfer. Article 66.2 of TRIPS obligated developed countries to provide incentives for technology transfer to least-developed countries. Article 67 required technical assistance for implementing TRIPS obligations. Wong argued that these provisions had been largely neglected in practice and proposed specific mechanisms through which Central American governments could press for their enforcement.
The article also addressed the role of patent disclosure requirements as a tool for knowledge diffusion. When patent applications are published, the technical knowledge they contain becomes available to local researchers and engineers, even though the patented invention itself cannot be freely used. Wong argued that effective use of this disclosure function required investment in technical infrastructure and human capital — areas where international development assistance could complement domestic policy.
A Regional Approach
Wong’s central proposal was that Central American nations would be more effective negotiating IP policy as a bloc rather than individually. Existing regional institutions such as the Central American Integration System (SICA) and the Secretariat for Central American Economic Integration (SIECA) could coordinate IP policy positions in international forums, pool technical expertise for patent examination, and develop shared databases of prior art relevant to the region’s economic priorities.
This regional approach echoed strategies used by other developing country coalitions in WTO negotiations, and connected to the broader debate about how international governance frameworks allocate resources between developed and developing nations.
Frequently Asked Questions
What is the TRIPS Agreement?
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international treaty administered by the WTO that sets minimum standards for IP protection among member nations. It was adopted in 1994 as part of the Uruguay Round of GATT negotiations.
What TRIPS flexibilities are available to developing countries?
TRIPS includes compulsory licensing (allowing generic production under certain conditions), parallel importation (importing patented goods from cheaper markets), and transition periods for implementation. The 2001 Doha Declaration affirmed that TRIPS should support public health objectives.
How does CAFTA-DR affect TRIPS flexibilities for Central America?
CAFTA-DR imposed TRIPS-plus obligations including extended patent terms, data exclusivity, and restrictions on compulsory licensing. These provisions narrowed the policy space available to Central American governments to use TRIPS flexibilities for development purposes.
Related articles: Medicines Patent Pool · Geosynchronous Orbit and Sovereignty · Hatch-Waxman and Pharmaceutical Patents · EU Data Protection